Adjunctive therapy appears to benefit only pancreatic head tumors and not body and tail tumors after surgical resection, a new study by Cleveland Clinic investigators suggests. Davendra Sohal, MD, MPH, staff in the Department of Hematology and Medical Oncology, collaborated with colleagues including Alok Khorana, MD, FASCO, Director, Gastrointestinal Malignancies Program, to evaluate a potential relationship between tumor site and benefit from adjuvant, neoadjuvant and perioperative therapies for pancreatic cancer. Results appear in Surgical Oncology.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Multi-agent chemotherapy regimens are one of the few developments supporting improved overall survival (OS) in pancreatic adenocarcinoma. Oncologists are beginning to agree that early systemic therapy can improve outcomes, but most evidence supporting adjunctive therapy for resected pancreatic cancer focuses on head tumors. “We wanted to know if tumor location matters,” says Dr. Sohal, “so that we can better pinpoint which patients benefit from adjunctive therapies.”
The team completed a comprehensive analysis of patients (N = 27,930) with resected pancreatic adenocarcinoma in the National Cancer Database. The study population included patients diagnosed with stage I and II pancreatic cancer between 2003 and 2013 who underwent resection of the pancreatic primary and whose records mentioned tumor site (head, body or tail).
The median age of patients was 66 years; 51 percent were male, and 86 percent were white. Most of the tumors were head (74.4 percent), followed by tail (16.3 percent) and body (9.3 percent). More than three-fourths of cancers were stage II, and 81 percent had negative margins. Median OS was 24 months (21.6 for head, 34.5 for body and 42.5 for tail).
In univariable testing, the use of adjunctive therapy was associated with worse OS for tail and body tumors. Multivariable analysis confirmed a clear interaction between the site of the primary tumor and treatment. Multivariable models separated by tumor site showed a significant association between treatment and pathologic stage for head tumors but not for body and tail. The benefit was greatest with perioperative therapy. Another univariable analysis showed that adjunctive therapy was only beneficial for clinical stage II head tumors.
“Our analysis also showed that tail and body tumors are associated with significantly better survival,” says Dr. Khorana. “We of course need prospective studies to further examine this association, but our study offers the most statistically robust evidence to date.”
Image: This image shows magnetic iron nanoparticles that target cells with IGF-1R receptors, and are conjugated to a chemotherapy drug (dark blue). In the tumor stroma of a mouse model of pancreatic cancer, the nanoparticles delivered the chemotherapy to tumor-associated macrophages expressing IGF-1R (red) and CD68 (green). Source: National Cancer Institute.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
